Holdings
Invesco Biotechnology & Genome ETF
As of Jul 31, 2026, Invesco Biotechnology & Genome ETF reported 29 positions worth US$278M. Largest: Regeneron Pharmaceuticals, Inc., Amgen Inc. and CareDx, Inc. What it bought and sold, with each filing.
Holdings
- Part of
- Invesco
- Positions
- 29
- Value as reported
- US$278M
- Holdings as of
- Jul 31, 2026
- Last filed
- Sep 28, 2026
| Company | Shares | Value as reported | % of portfolio | Change | As of |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. NASDAQ:REGN | 20,233 | US$15.4M | 5.5% | +3,549 | Jul 31, 2026 |
| Amgen Inc. NASDAQ:AMGN | 38,223 | US$14.7M | 5.2% | +4,572 | Jul 31, 2026 |
| CareDx, Inc. NASDAQ:CDNA | 325K | US$14.2M | 5.0% | −39,886 | Jul 31, 2026 |
| Vertex Pharmaceuticals Incorporated NASDAQ:VRTX | 29,460 | US$14.1M | 5.0% | New | Jul 31, 2026 |
| Royalty Pharma plc NASDAQ:RPRX | 238K | US$13.9M | 4.9% | +83,631 | Jul 31, 2026 |
| Biogen Inc. NASDAQ:BIIB | 66,507 | US$13.5M | 4.8% | +482 | Jul 31, 2026 |
| Gilead Sciences, Inc. NASDAQ:GILD | 96,026 | US$12.5M | 4.4% | +8,762 | Jul 31, 2026 |
| United Therapeutics Corporation NASDAQ:UTHR | 22,197 | US$11.5M | 4.1% | −5,015 | Jul 31, 2026 |
| Bio-Techne Corp NASDAQ:TECH | 146K | US$10.5M | 3.7% | +24,015 | Jul 31, 2026 |
| Illumina, Inc. NASDAQ:ILMN | 48,231 | US$9.89M | 3.5% | −56,601 | Jul 31, 2026 |
| Protagonist Therapeutics, Inc. NASDAQ:PTGX | 70,055 | US$9.57M | 3.4% | −10,360 | Jul 31, 2026 |
| Vericel Corporation NASDAQ:VCEL | 200K | US$9.21M | 3.3% | +16,572 | Jul 31, 2026 |
| Alnylam Pharmaceuticals, Inc. NASDAQ:ALNY | 43,457 | US$8.93M | 3.2% | +4,751 | Jul 31, 2026 |
| Incyte Corporation NASDAQ:INCY | 72,136 | US$8.62M | 3.1% | −55,363 | Jul 31, 2026 |
| Repligen Corporation NASDAQ:RGEN | 60,807 | US$8.57M | 3.0% | +8,624 | Jul 31, 2026 |
| ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 329K | US$8.52M | 3.0% | +43,677 | Jul 31, 2026 |
| Halozyme Therapeutics, Inc. NASDAQ:HALO | 102K | US$8.41M | 3.0% | +2,049 | Jul 31, 2026 |
| Qiagen N.V. NYSE:QGEN | 197K | US$8.16M | 2.9% | +52,189 | Jul 31, 2026 |
| BioMarin Pharmaceutical Inc. NASDAQ:BMRN | 132K | US$7.95M | 2.8% | +20,236 | Jul 31, 2026 |
| Neurocrine Biosciences, Inc. NASDAQ:NBIX | 44,979 | US$7.5M | 2.7% | −8,681 | Jul 31, 2026 |
| Exelixis, Inc. NASDAQ:EXEL | 140K | US$7.43M | 2.6% | −15,538 | Jul 31, 2026 |
| BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX | 827K | US$7.43M | 2.6% | −96,495 | Jul 31, 2026 |
| Veracyte, Inc. NASDAQ:VCYT | 158K | US$7.34M | 2.6% | −38,468 | Jul 31, 2026 |
| Collegium Pharmaceutical, Inc. NASDAQ:COLL | 207K | US$7.34M | 2.6% | +51,774 | Jul 31, 2026 |
| Omeros Corporation NASDAQ:OMER | 601K | US$7.12M | 2.5% | New | Jul 31, 2026 |
| PTC Therapeutics, Inc. NASDAQ:PTCT | 104K | US$7.04M | 2.5% | +1,664 | Jul 31, 2026 |
| AnaptysBio, Inc. NASDAQ:ANAB | 121K | US$6.47M | 2.3% | New | Jul 31, 2026 |
| Sarepta Therapeutics, Inc. NASDAQ:SRPT | 420K | US$6.24M | 2.2% | New | Jul 31, 2026 |
| Ardelyx, Inc. NASDAQ:ARDX | 1.12M | US$5.55M | 2.0% | New | Jul 31, 2026 |